Biologics/Immunotherapy News

The FDA has approved Palforzia for children aged 1 to 3 years who have a peanut allergy that has been diagnosed by a physician, according to a press release from its manufacturer, Stallergenes Greer.

Mepolizumab and benralizumab had similar safety profiles for patients with severe eosinophilic asthma despite their different mechanisms, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Responses to baricitinib and dupilumab were notable and similar among patients with moderate to severe atopic dermatitis in a real-world setting, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

In February, the FDA approved omalizumab for the reduction of food allergic reactions. First approved in 2003 for allergic asthma, this anti-IgE monoclonal antibody developed by Genentech and Novartis inhibits the allergic reaction process.

Significant disparities exist between patients with peanut allergies who are currently receiving oral immunotherapy and those who are not, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Families of children with peanut allergies that pursued oral immunotherapy cited remission and the potential for disease modification as their reason, according to a study published in The Journal of Allergy and Immunology: In Practice.

SAN DIEGO — Patients with severe asthma experienced fewer exacerbations with 6 months of treatments with biologics, according to a study presented at the American Thoracic Society International Conference.

New guidance was established for clinicians in the U.K. in order to implement the use of Palforzia in oral immunotherapy for patients with a peanut allergy, according to a study published in Clinical & Experimental Allergy.

SAN DIEGO — Asthma remission may occur more often with the use of biologics, but non-white patients receive fewer biologics than white patients, according to an abstract presented at the American Thoracic Society International Conference.

As biologics become more popular for a growing number of indications, practices need to figure out the most cost-effective ways to provide these treatments to their patients.